Similarly, Qian et al. demonstrated that combined therapy with cetuximab (an epidermal growth factor receptor [EGFR] monoclonal antibody) and the COX-2 inhibitor CXB significantly reduced tumor volume in OSCC xenograft models [28]. Here, PTGS2 is linked to neoplasm.